Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$486 Mln
P/E Ratio
--
P/B Ratio
3.81
Industry P/E
--
Debt to Equity
0.07
ROE
-1 %
ROCE
-92.97 %
Div. Yield
0 %
Book Value
2.46
EPS
-2.46
CFO
$-467.64 Mln
EBITDA
$-626.80 Mln
Net Profit
$-578.32 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cogent Biosciences (COGT)
| -43.97 | -38.80 | -46.25 | -32.35 | -20.63 | 24.51 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Cogent Biosciences (COGT)
| 32.35 | -49.13 | 34.73 | -23.60 | 289.82 | -83.63 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial... designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts. Address: 275 Wyman Street, Waltham, MA, United States, 02451 Read more
President, CEO & Director
Mr. Andrew R. Robbins M.B.A.
President, CEO & Director
Mr. Andrew R. Robbins M.B.A.
Headquarters
Waltham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cogent Biosciences Inc (COGT) stood at $ 328 Mln as on 31-Dec-24
The share price of Cogent Biosciences Inc (COGT) is $4.37 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Cogent Biosciences Inc (COGT) has given a return of -20.63% in the last 3 years.
Cogent Biosciences Inc (COGT) has a market capitalisation of $ 486 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Cogent Biosciences Inc (COGT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cogent Biosciences Inc (COGT) and enter the required number of quantities and click on buy to purchase the shares of Cogent Biosciences Inc (COGT).
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts. Address: 275 Wyman Street, Waltham, MA, United States, 02451
The CEO & director of Mr. Andrew R. Robbins M.B.A.. is Cogent Biosciences Inc (COGT), and CFO & Sr. VP is Mr. Andrew R. Robbins M.B.A..
There is no promoter pledging in Cogent Biosciences Inc (COGT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Cogent Biosciences Inc. (COGT) | Ratios |
|---|---|
|
Return on equity(%)
|
-99.54
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cogent Biosciences Inc (COGT) was $0 Mln.
$0.10
(
